Brain Cancer | Specialty

The Optune Device in Glioblastoma: Patient Selection

February 9th 2016

Clinical Experience with Electric Field Therapy in Glioblastoma

February 9th 2016

Treatment Options in Recurrent Glioblastoma

February 9th 2016

Electric Field Therapy in Newly-Diagnosed GBM

February 9th 2016

Systemic Therapy Options in Glioblastoma

February 9th 2016

Goals of Resection in Glioblastoma

February 9th 2016

Multidisciplinary Care in Glioblastoma

February 9th 2016

Diagnostic and Prognostic Markers in Glioblastoma

February 9th 2016

Pathologic Features and Classification of Glioblastoma

February 9th 2016

Progress and Challenges in Glioblastoma

February 9th 2016

Dr. Murphy on Glioma Prognostic Factors in Younger Patients

January 6th 2016

Erin Murphy, MD, associate staff, Department of Radiation Oncology, Cleveland Clinic, discusses a study examining prognostic factors of patients with glioma.

Reardon on Promising Results With Rindopepimut in Brain Cancer

December 30th 2015

David Reardon, MD, discusses the ReACT study and the potential of rindopepimut and other immunotherapy agents for the treatment of patients with brain cancers, specifically glioblastoma.

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

November 23rd 2015

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Dr. Gilbert on Precision Medicine in Glioblastoma

November 23rd 2015

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Optimizing Precision Medicine Approaches in Glioblastoma

November 22nd 2015

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

'Groundbreaking' Global Brain Cancer Trial Planned

November 22nd 2015

An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

November 22nd 2015

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBM

November 22nd 2015

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

Dr. Mrugala on Extending Treatment With Temozolomide in Glioblastoma

November 21st 2015

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Rindopepimut Combo Continues to Show Strong OS Benefit in Relapsed GBM

November 21st 2015

Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.